B. Riley lowered the firm’s price target on InfuSystem (INFU) to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The company remains focused on improving profitability while pursuing growth opportunities such as advanced wound care and chemo mouthpiece, the analyst tells investors in a research note. Riley expects InfuSystem to continue to repurchase shares throughout the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INFU: